World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update
Antimicrobial resistance is a major public health problem globally. Likewise, forms of
tuberculosis (TB) resistant to first-and second-line TB medicines present a major challenge …
tuberculosis (TB) resistant to first-and second-line TB medicines present a major challenge …
[HTML][HTML] Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic …
DJH Tan, CH Ng, SY Lin, XH Pan, P Tay… - The Lancet …, 2022 - thelancet.com
Background The clinical presentation and outcomes of non-alcoholic fatty liver disease
(NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular …
(NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular …
[图书][B] WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update
World Health Organization - 2022 - books.google.com
The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug-
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …
Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country
Objective: To compare the effectiveness of second line injectables containing shorter
(duration 9–12 months) and longer treatment regimens (LTR, duration≥ 20 months) among …
(duration 9–12 months) and longer treatment regimens (LTR, duration≥ 20 months) among …
Treatment of highly drug-resistant pulmonary tuberculosis
F Conradie, AH Diacon, N Ngubane… - … England Journal of …, 2020 - Mass Medical Soc
Background Patients with highly drug-resistant forms of tuberculosis have limited treatment
options and historically have had poor outcomes. Methods In an open-label, single-group …
options and historically have had poor outcomes. Methods In an open-label, single-group …
[图书][B] WHO consolidated guidelines on drug-resistant tuberculosis treatment
World Health Organization - 2019 - apps.who.int
Executive summary Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult
to treat than drug-susceptible ones, and threaten global progress towards the targets set by …
to treat than drug-susceptible ones, and threaten global progress towards the targets set by …
Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis
Background & Aims Fibrosis is a key determinant of clinical outcomes in nonalcoholic fatty
liver disease (NAFLD), but time-dependent risk of mortality has not been reported in …
liver disease (NAFLD), but time-dependent risk of mortality has not been reported in …
[HTML][HTML] MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention
and rehabilitation requires frequent update of existing guidelines. This review is aimed at …
and rehabilitation requires frequent update of existing guidelines. This review is aimed at …
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
Background Treatment of multidrug-resistant tuberculosis requires long-term therapy with a
combination of multiple second-line drugs. These drugs are associated with numerous …
combination of multiple second-line drugs. These drugs are associated with numerous …
Management of drug-resistant tuberculosis
Drug-resistant tuberculosis is a major public health concern in many countries. Over the past
decade, the number of patients infected with Mycobacterium tuberculosis resistant to the …
decade, the number of patients infected with Mycobacterium tuberculosis resistant to the …